- Record: found
- Abstract: found
- Article: not found
Circulating tumor cells predict survival benefit from treatment in metastatic castration-resistant prostate cancer.
Johann S de Bono
1 ,
Howard I Scher ,
R Bruce Montgomery ,
Christopher Parker ,
M Craig Miller ,
Henk Tissing ,
Gerald V Doyle ,
Leon W W M Terstappen ,
Kenneth J Pienta ,
Derek Raghavan
Oct 01 2008
There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.
Abstract
A method for enumerating circulating tumor cells (CTC) has received regulatory clearance. The primary objective of this prospective study was to establish the relationship between posttreatment CTC count and overall survival (OS) in castration-resistant prostate cancer (CRPC). Secondary objectives included determining the prognostic utility of CTC measurement before initiating therapy, and the relationship of CTC to prostate-specific antigen (PSA) changes and OS at these and other time points.